Progress in reducing measles mortality--worldwide, 1999-2003
- PMID: 15744229
Progress in reducing measles mortality--worldwide, 1999-2003
Abstract
Measles remains an important cause of childhood mortality, especially in developing countries. In the joint Strategic Plan for Measles Mortality Reduction, 2001-2005, the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) targeted 45 priority countries with high measles burden for implementation of a comprehensive strategy for accelerated and sustained measles mortality reduction. Components of this strategy include achieving high routine vaccination coverage (>/=90%) in every district and ensuring that all children receive a second opportunity for measles immunization. In May 2003, the World Health Assembly endorsed a resolution urging member countries to reduce deaths attributed to measles by half (compared with 1999 estimates) by the end of 2005. This report updates progress toward this goal and summarizes recent recommendations on methods to estimate global measles mortality.
Similar articles
-
Progress in reducing global measles deaths, 1999-2004.MMWR Morb Mortal Wkly Rep. 2006 Mar 10;55(9):247-9. MMWR Morb Mortal Wkly Rep. 2006. PMID: 16528234
-
Progress in global measles control and mortality reduction, 2000-2006.MMWR Morb Mortal Wkly Rep. 2007 Nov 30;56(47):1237-41. MMWR Morb Mortal Wkly Rep. 2007. PMID: 18046301
-
Progress in global measles control and mortality reduction, 2000-2007.MMWR Morb Mortal Wkly Rep. 2008 Dec 5;57(48):1303-6. MMWR Morb Mortal Wkly Rep. 2008. PMID: 19052529
-
The unfinished measles immunization agenda.J Infect Dis. 2003 May 15;187 Suppl 1:S1-7. doi: 10.1086/368226. J Infect Dis. 2003. PMID: 12721885 Review.
-
Determining measles-containing vaccine demand and supply: an imperative to support measles mortality reduction efforts.J Infect Dis. 2003 May 15;187 Suppl 1:S22-8. doi: 10.1086/368274. J Infect Dis. 2003. PMID: 12721888 Review.
Cited by
-
Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.Hum Vaccin Immunother. 2017 Jul 3;13(7):1523-1530. doi: 10.1080/21645515.2017.1302629. Epub 2017 Mar 31. Hum Vaccin Immunother. 2017. PMID: 28362563 Free PMC article. Clinical Trial.
-
Measles transmission following the tsunami in a population with a high one-dose vaccination coverage, Tamil Nadu, India 2004-2005.BMC Infect Dis. 2006 Sep 19;6:143. doi: 10.1186/1471-2334-6-143. BMC Infect Dis. 2006. PMID: 16984629 Free PMC article.
-
Reversible inhibition of the fusion activity of measles virus F protein by an engineered intersubunit disulfide bridge.J Virol. 2007 Aug;81(16):8821-6. doi: 10.1128/JVI.00754-07. Epub 2007 Jun 6. J Virol. 2007. PMID: 17553889 Free PMC article.
-
Potent non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex.J Med Chem. 2008 Jul 10;51(13):3731-41. doi: 10.1021/jm701239a. Epub 2008 Jun 5. J Med Chem. 2008. PMID: 18529043 Free PMC article.
-
The role of Toll-like receptor 4 polymorphisms in vaccine immune response.Pharmacogenomics J. 2016 Feb;16(1):96-101. doi: 10.1038/tpj.2015.21. Epub 2015 Mar 31. Pharmacogenomics J. 2016. PMID: 25823688 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical